Physician profile
Manavendra Bakhshi
NPI 1710961941
$250,014.64
in general payments reported to CMS, 2019-2025
25 companies · $6,865 in 2025
The $6,865 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $27K · 2021: $25K · 2022: $65K · 2023: $42K · 2024: $26K · 2025: $6,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $13K · Travel and Lodging: $1,858 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,917.75 |
| Food and Beverage | $13,060.81 |
| Travel and Lodging | $1,858.43 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $83,187.29 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $61,473.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $50,475.67 | 2019-2025 | Lokelma, Farxiga, Breztri |
| Astellas Pharma US INC | $17,021.73 | 2019-2023 | Lexiscan |
| Amarin Pharma, INC. | $15,400.89 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $6,797.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,301.81 | 2019-2025 | Jardiance, Spiriva, Synjardy |
| Boston Scientific Corporation | $2,356.11 | 2019-2025 | Watchman Flx, Watchman Access System |
| Glaxosmithkline, LLC. | $1,942.98 | 2019-2025 | Trelegy Ellipta |
| Medtronic, INC. | $1,851.69 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Linq II |
| Medtronic Vascular, INC. | $1,723.41 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $796.16 | 2021-2023 | Optimizer |
| Biotronik INC. | $791.01 | 2019-2024 | Rivacor 7 Dr-T, Renamic Neo, Biomonitor |
| Amgen INC. | $635.11 | 2024-2025 | Repatha, Repatha |
| Azurity Pharmaceuticals, INC. | $337.99 | 2024-2025 | Edarbyclor, Edarbi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $210.96 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $193.83 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $189.94 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $115.99 | 2019 | |
| Pfizer INC. | $71.93 | 2019-2025 | |
| Janssen Biotech, INC. | $53.64 | 2020-2021 | |
| Irhythm Technologies, INC. | $23.76 | 2021 | |
| Corcept Therapeutics | $21.51 | 2023 | Korlym |
| Esperion Therapeutics, INC. | $20.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manavendra Bakhshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.